Moderna MRNA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Contract with Customer, Liability by Product | ||||||
| Net product sales | $95M-38.3% | $107M-43.1% | $144M-67.5% | $221M-70.1% | $154M-73.4% | |
| Other revenue | $161M+455% | $145M+530% | $176M— | $62M+210% | $29M— | |
| Total Revenue by Product | ||||||
| Collaboration Arrangement, Including Arrangements With Affiliate | $5M+400% | $1M-92.3% | $7M-75.0% | $4M-42.9% | $1M— | |
| Grant revenue | $0-100% | $2M-80.0% | $14M+100% | $5M-97.2% | $1M— | |
| Licensing and royalty revenue | $0-100% | $0-100% | $2M-71.4% | $2M-93.3% | $8M— | |
| Stand-ready manufacturing revenue | $32M+167% | —— | —— | —— | $12M— | |
| Additions by Product | ||||||
| Net product sales | $0— | $24M+2,300% | $0-100% | $84M-53.8% | $0-100% | |
| Other revenue | $53M+279% | $2M— | $146M— | $50M— | $14M— | |
| Contract With Customer, Liability, Deductions During Period by Product | ||||||
| Net product sales | $12M-64.7% | $61M-76.2% | $77M-76.3% | $17M-22.7% | $34M-27.7% | |
| Other revenue | $37M+363% | $33M— | $32M— | $17M— | $8M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Moderna break its business down?
- Moderna (MRNA) reports contract with customer, liability by product across 2 parts — Net product sales and Other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Moderna's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Moderna's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
